{
    "clinical_study": {
        "@rank": "137833", 
        "arm_group": [
            {
                "arm_group_label": "Sarpogrelate", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Phase 4 Study to evaluate the safety and effect on decreasing subjects' albuminuria who have\n      Type 2 Diabetes by using sarpogrelate and placebo."
        }, 
        "brief_title": "Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetic Nephropathy", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus, Type 2", 
                "Diabetic Nephropathies", 
                "Kidney Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  person who signed on ICF\n\n          -  Type 2 diabetic patient who have microalbuminuria or overt proteinuria\n\n          -  In case of hypertension patients, who keep the same medication steadily over last 4\n             weeks\n\n        Exclusion Criteria:\n\n          -  patients who have hypersensitivity on sarpogrelate or other salicylic acid\n\n          -  patients who should keep the antiplatelet agent because of acute cardiac disease or\n             peripheral vein disease\n\n          -  patients who took other anticoagulant agent within 1 month\n\n          -  patient who take ACEI OR ARB but not controlled(over 150/100mmHg)\n\n          -  Type 1 diabetes patients\n\n          -  Patient who have cardiac or liver problem\n\n          -  Cr: >1.8mg/dl or GFR: <40ml/min\n\n          -  malignant tumor patients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "166", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01869881", 
            "org_study_id": "YCM009"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sarpogrelate", 
                "description": "Sarpogrelate 100mg 2 tablets, bid, 400mg/day", 
                "intervention_name": "Anplag(Sarpogrelate)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo 100mg 2 tablets, bid, 400mg/day", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sarpogrelate"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 4, 2013", 
        "location": {
            "contact": {
                "email": "gusdhr2532@naver.com", 
                "last_name": "Hyun-Ok Kim, RN"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Korea University, Anam"
            }, 
            "investigator": {
                "last_name": "D.S Choi, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes", 
        "overall_contact": {
            "email": "gusdhr2532@naver.com", 
            "last_name": "Hyun-Ok Kim, RN"
        }, 
        "overall_official": {
            "affiliation": "Korea University Hospital, Anam", 
            "last_name": "D.S Choi, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "adverse event and rate of adverse event", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "treatment period(24 weeks)"
            }, 
            {
                "description": "change of percentage", 
                "measure": "ACR(Urine Albumin/Creatinine ratio)", 
                "safety_issue": "No", 
                "time_frame": "treatment period(24 weeks)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01869881"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "improvement efficiency rate of ACR comparing to baseline Definition of improvement efficiency : ACR become normal(<20mg/g Cr) or ACR is decreased more than 50% comparing to data before taking IP(Investigators' product)", 
                "measure": "ACR(Urine Albumin/Creatinine ratio)", 
                "safety_issue": "No", 
                "time_frame": "Treatment period(24 weeks)"
            }, 
            {
                "description": "changes comparing to baseline data", 
                "measure": "urinary 5-HIAA(5-Hydroxyindoleacetic acid), type 4 collagen", 
                "safety_issue": "No", 
                "time_frame": "treatment period(24 weeks)"
            }, 
            {
                "description": "improved amount comparing to baseline data", 
                "measure": "ACR(Urine Albumin/Creatinine ratio)", 
                "safety_issue": "No", 
                "time_frame": "treatment period(24 weeks)"
            }, 
            {
                "description": "rate of normalized ACR", 
                "measure": "ACR(Urine Albumin/Creatinine ratio)", 
                "safety_issue": "No", 
                "time_frame": "treatment period(24 weeks)"
            }, 
            {
                "description": "improved amount of Creatinine", 
                "measure": "Creatinine", 
                "safety_issue": "No", 
                "time_frame": "treatment period(24 weeks)"
            }, 
            {
                "description": "improved rate comparing to baseline data", 
                "measure": "PCR(Protein to Creatinine ratio in Urine)", 
                "safety_issue": "No", 
                "time_frame": "treatment period(24 weeks)"
            }
        ], 
        "source": "Yuhan Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yuhan Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}